Novo Nordisk's lawsuit over Eli Lilly GLP-1 ads

Co wiedzieliśmy na początku

• Novo Nordisk filed a false-advertising complaint against Eli Lilly in New Jersey federal court on July 21, 2026.
• Novo is seeking a permanent injunction requiring Lilly to pull the comparative advertising.
• The core allegation is that Lilly's ads compare top-dose Zepbound and Mounjaro to lower-dose Wegovy and Ozempic, omitting newer higher-dose Novo formulations.

Wtedy jeszcze otwarte

• Any verbatim Lilly on-the-record statement beyond the general "truthful and based on the best available scientific evidence" framing. The source file does not include one.
• How the court will treat the question of which doses are properly comparable, and which clinical trials it considers current.
• Whether the case produces a settlement, a ruling on the injunction, or a long discovery fight.

Na co mieliśmy zwracać uwagę

• Whether Lilly pulls, modifies, or continues the disputed advertising while the case is pending.
• Whether Novo's filings prompt parallel actions, including any Lanham Act or state-level complaints beyond New Jersey.
• How the dosing-comparison fight reshapes comparative advertising across the rest of the GLP-1 category.